Investigating a new therapy to prevent cognitive decline in Alzheimer's disease
Tumor susceptibility gene 101, a new microglial therapy candidate for Alzheimer’s disease to prevent cognitive decline
This study is exploring a new way to help people with Alzheimer's by changing a gene that affects brain immune cells, which could help clear out harmful proteins and improve thinking and memory.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project ID | NIH-10710931 on NIH RePORTER |
What this research studies
This research focuses on a potential new treatment for Alzheimer's disease by targeting a specific gene involved in the function of microglia, the brain's immune cells. The study aims to manipulate the secretion of extracellular vesicles from microglia to reduce the accumulation of toxic proteins associated with Alzheimer's, such as tau. Using a mouse model of the disease, researchers will assess cognitive function and the progression of neurodegeneration after altering the gene's activity. The findings could lead to innovative therapies that improve brain health and cognitive abilities in Alzheimer's patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for or diagnosed with Alzheimer's disease, particularly those with early cognitive decline.
Not a fit: Patients with advanced Alzheimer's disease or those with other forms of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking therapy that slows or prevents cognitive decline in individuals with Alzheimer's disease.
How similar studies have performed: Other research has shown promise in targeting microglial functions to mitigate neurodegeneration, suggesting that this approach could be effective.
Where this research is happening
Jacksonville, United States
- Mayo Clinic Jacksonville — Jacksonville, United States (Active)
Researchers
- Principal investigator: Ikezu, Seiko — Mayo Clinic Jacksonville
- Study coordinator: Ikezu, Seiko
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.